Delixy Holdings (NASDAQ:DLXY) reported a contraction in top-line growth for the first six months of 2025, as the recently listed oil trader navigated a volatile energy market and narrowed its focus toward higher-margin operations.
California Water Service (NYSE:CWT) will implement a 3% interim rate increase across most of its districts starting Jan. 1, after state regulators authorized the temporary measure to bridge a delay in the utility’s broader triennial rate review.
ARS Pharmaceuticals (NASDAQ:SPRY) said China’s drug regulator has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions in adults and children weighing at least 30 kilograms, marking the first epinephrine product authorized for community use in the country.
Tonix Pharmaceuticals (NASDAQ:TNXP) said it is advancing development plans for TNX-4800, a long-acting human monoclonal antibody designed for the prevention of seasonal Lyme disease, as the company prepares for regulatory discussions on potential late-stage clinical pathways.
GATX Corp. (NYSE:GATX) said it and Brookfield Infrastructure Partners L.P. (NYSE:BIP) have received all required regulatory approvals to complete their previously announced transaction to acquire Wells Fargo’s rail operating lease portfolio
Bitcoin’s (CRYPTO:BTC) rally towards $90,000 has slowed as weaker demand and muted onchain activity weigh on near-term momentum.
Adlai Nortye (NASDAQ:ANL) said it has entered into an exclusive licensing agreement with ASK Pharm for the development and commercialization of its proprietary pan-RAS (ON) inhibitor, AN9025, in Greater China.
Praxis Precision Medicines (NASDAQ:PRAX) said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ulixacaltamide, a selective T-type calcium channel inhibitor being developed for the treatment of essential tremor, accelerating the regulatory path for the experimental therapy.
INOVIO (NASDAQ:INO) said the U.S. Food and Drug Administration has accepted for review its Biologics License Application for INO-3107, a DNA medicine being developed as a potential treatment for adults with recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus.
Verisk (NASDAQ:VRSK) has terminated its definitive agreement to acquire AccuLynx after the Federal Trade Commission failed to complete its review of the transaction by the Dec. 26, 2025 termination date specified in the merger agreement.
Mereo BioPharma (NASDAQ:MREO) said Phase 3 trials of setrusumab (UX143) in osteogenesis imperfecta failed to meet their primary endpoints, dealing a setback to the late-stage program as the company moves to cut spending and reassess priorities.
SELLAS Life Sciences (NYSE:SLS) said it is approaching the final analysis milestone in its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in acute myeloid leukemia, following an aggregate event count update from its contract research organization.
